Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Second bone marrow transplantation in eight children.

M Mattot1, J Ninane, C Vermylen

  • 1Department of Paediatric Haematology and Oncology, Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Pediatric Hematology and Oncology
|October 1, 1992
PubMed
Summary

Second bone marrow transplants in children showed similar recovery and infection rates but lower rejection and graft-versus-host disease. However, prognosis for relapsed chronic leukemia did not improve after a second bone marrow transplant.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Contribution of plasma membrane lipid domains to red blood cell (re)shaping.

Scientific reports·2017
Same author

Computational and molecular approaches for predicting unreported causal missense mutations in Belgian patients with haemophilia A.

Haemophilia : the official journal of the World Federation of Hemophilia·2011
Same author

Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.

Medecine tropicale : revue du Corps de sante colonial·2011
Same author

Ten years after the first inspection of a candidate European centre, an EBMT registry analysis suggests that clinical outcome is improved when hematopoietic SCT is performed in a JACIE accredited program.

Bone marrow transplantation·2011
Same author

Neonatal acute myeloid leukemia in an infant whose mother was exposed to diethylstilboestrol in utero.

Pediatric blood & cancer·2009
Same author

Use of hydroxyurea from childhood to adult age in sickle cell disease: semen analysis.

Haematologica·2008

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Transplantation Immunology

Background:

  • Bone marrow transplantation (BMT) is a critical treatment for various pediatric hematological disorders.
  • Successive BMTs are considered in cases of graft failure or disease relapse.
  • Limited data exists on the outcomes of sequential BMTs in pediatric populations.

Purpose of the Study:

  • To evaluate the outcomes of second bone marrow transplantations in children.
  • To compare the efficacy and safety of initial versus second BMTs.
  • To assess the impact of second BMT on graft rejection, graft-versus-host disease, and overall prognosis.

Main Methods:

  • Retrospective analysis of eight children who received two successive bone marrow transplantations between 1985 and 1989.

Related Experiment Videos

  • Review of initial diagnoses including chronic myelomonocytic leukemia, chronic myelocytic leukemia, acute M7 nonlymphoblastic leukemia, sickle cell anemia, and thalassemia major.
  • Analysis of conditioning regimens for the second transplant, including high-dose chemotherapy, antithymocytic globulin, and total nodal irradiation.

    • Main Results:

    • Hematological recovery was comparable after both first and second bone marrow transplantations.
    • Infectious complications did not increase after the second graft compared to the first.
    • Lower rates of graft rejection and graft-versus-host disease were observed after the second BMT, likely due to intensified immunosuppression.

    Conclusions:

    • Second bone marrow transplantation in children can achieve similar hematological recovery and infection rates as the first.
    • Intensified immunosuppression may reduce rejection and graft-versus-host disease in subsequent transplants.
    • A second bone marrow transplant does not appear to improve the prognosis for children with chronic leukemia relapsing after an initial graft.